HSDT
Solana Company
There isn't enough reported data to score HSDT yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HSDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
HSDT's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HSDT PE Valuation
HSDT has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
HSDT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect HSDT's losses to shrink, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HSDT Earnings Per Share
HSDT is still losing money, but far less than before: $126,750.00 per share over the past year, against $695,625.00 at its worst in mid-2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over HSDT in the latest year-over-year earnings comparison.
HSDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.4M | +382% |
| Q2 2026 | $2.5M | +5774% |
| Q1 2026 | $3.6M | +7290% |
| Q4 2025 | $5.2M | +3339% |
| Q3 2025 | $697K | +1267% |
| Q2 2025 | $43K | -76% |
| Q1 2025 | $49K | -64% |
| Q4 2024 | $152K | +13% |
HSDT's revenue has grown year over year for five quarters in a row: $3M last quarter, up 382% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3091% | +8177 points |
| Q2 2026 | -1293% | +6432 points |
| Q1 2026 | -2751% | +5435 points |
| Q4 2025 | -3846% | -1775 points |
| Q3 2025 | -5086% | +2894 points |
| Q2 2025 | -7726% | -5929 points |
| Q1 2025 | -8186% | -5655 points |
| Q4 2024 | -2070% | -394 points |
HSDT has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
HSDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$2.4M | -$341K |
| Q3 2024 | -$2.8M | -$313K |
| Q2 2024 | -$2.9M | -$150K |
| Q1 2024 | -$3M | +$203K |
| Q4 2023 | -$2M | +$104K |
| Q3 2023 | -$2.5M | +$1.4M |
| Q2 2023 | -$2.7M | +$933K |
| Q1 2023 | -$3.2M | +$1.5M |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with HSDT at down 72%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
HSDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +102% | +5.1K shares |
| 1 year | +1032% | +9.2K shares |
| 3 years | +18557% | +10K shares |
HSDT has 10,075 diluted shares, up 1032% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.8M |
| Q2 2026 | $2.3M |
| Q1 2026 | $3.5M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over HSDT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
HSDT Net Leverage
HSDT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
HSDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 19.6 | Oversold |
HSDT's weekly RSI is 33 (neutral) and its Stochastic is 20 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HSDT PE vs Healthcare Sector
HSDT has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HSDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.30 | 18% below |
| 20 week MA | $2.10 | 10% below |
| 50 week MA | $2.24 | 16% below |
| 100 week MA | $91.2 | 98% below |
| 200 week MA | $2,397.1 | 100% below |
HSDT is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over HSDT on trend strength, trading above more of its moving averages.
HSDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,246,875.0 | $540,750.0 | -57% |
| 2021 | $540,750.0 | $208,500.0 | -61% |
| 2022 | $208,500.0 | $8,325.0 | -96% |
| 2023 | $8,325.0 | $6,030.0 | -28% |
| 2024 | $6,030.0 | $525.0 | -91% |
| 2025 | $525.0 | $2.78 | -99% |
| 2026 YTD | $2.78 | $1.89 | -32% |
HSDT has finished every year since 2020 lower, and it's down 32% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over HSDT on returns for 2026, with the stronger performance.